Spero Therapeutics SPRO 深 滬
等待開盤 10-22 09:30:00 美东时间
1.17
-0.050
-4.10%
華盛通- 最 高1.22
- 今 開1.21
- 成交量 26.57万股
- 最 低 1.165
- 昨 收 1.22
- 總市值 6813.47万
- 52周最高 3.08
- 市盈率 靜 8.06
- 換手率 0.46%
- 52周最低 1.08
- 委 比 44.91%
- 總股本 5823.48万
- 歷史最高 23.639
- 量 比 0.61
- 振 幅 4.51%
- 歷史最低 0.5052
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Spero Therapeutics收跌2.65%，成交额40.82万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:20
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Spero Therapeutics announced the approval of 233,000 restricted stock units (RSUs) and 323,000 stock options granted to new employees under its 2019 Inducement Plan. These awards, granted on October 1, 2026, vest over time and are intended to incentivize new hires. The stock options vest 25% on the first anniversary of employment, with the remainder vesting monthly over 36 months. RSUs vest in four equal annual installments. The company focuses o...
10-02 20:05
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Meta Platforms To $650? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wedbush raised the price target for Meta Platforms Inc (NASDAQ:META) from $595 to $650. Wedbush analyst Ygal A...
09-14 21:01
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $5 to $6.
09-14 18:42
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>Spero Therapeutics, Inc. granted 102,000 RSUs and 67,600 stock options to new employees under its 2019 Inducement Plan. The stock options vest 25% on September 1, 2027, with the rest vesting monthly over 36 months. RSUs vest in four equal annual installments starting September 1, 2027. Both are subject to continued employment and the terms of the 2019 Inducement Plan. Spero focuses on developing next-generation medicines for immune-mediated di...
09-03 20:05
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
Spero Therapeutics, Inc. announced that CEO Esther Rajavelu will present at the H.C. Wainwright 28th Annual Global Healthcare Conference in New York City on September 15, 2026, at 1:30 PM ET. The presentation will be available via webcast and replay for 90 days post-conference. Spero focuses on advancing next-generation medicines for immune-mediated diseases.
09-02 20:01
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
Spero Therapeutics Files Prospectus To Offer Up To $300M In Securities
08-29 05:08
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics announced several key milestones in Q2 2026, including an exclusive license agreement for SP001, FDA approval of Utebzi for complicated urinary tract infections, a $105 million non-dilutive financing, and the appointment of Debra Zack, M.D., Ph.D., as Chief Medical Officer. The company reported a net loss of $9.6 million for the quarter, with cash and cash equivalents of $50.8 million, extended to mid-2029 with the financing pr...
08-12 20:01
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics (Nasdaq: SPRO) announced it will report its second-quarter 2026 financial results on August 12, 2026, after market close. Management will host a conference call and live webcast at 5:00 pm EDT to discuss the results and provide updates. The call can be accessed via phone or webcast links provided. Spero, a clinical-stage biopharmaceutical company, focuses on advancing next-generation medicines in immunology and inflammation.
08-04 20:01
